NYSE:PFE - Pfizer Stock Price, Price Target & More

$36.34 -0.15 (-0.41 %)
(As of 04/19/2018 01:25 PM ET)
Previous Close$36.49
Today's Range$36.27 - $36.69
52-Week Range$31.67 - $39.43
Volume7.82 million shs
Average Volume23.62 million shs
Market Capitalization$216.27 billion
P/E Ratio13.73
Dividend Yield3.74%
Beta0.9

About Pfizer (NYSE:PFE)

Pfizer logoPfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care. This segment offers products primarily under the Prevnar 13/Prevenar 13, Xeljanz, Eliquis, Lyrica, Enbrel, Ibrance, Xtandi, Advil, and Centrum brands. The EH segment offers products that would lose or have lost marketing patent protection; branded generic products; generic sterile injectable products; biosimilars; and anti-infectives. It provides products under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, Viagra, Inflectra/Remsima, Pristiq, Zyvox, Vfend, Revatio, Inspra, Medrol, Sulperazon, Fragmin, Tygacil, Nivestim, and Retacrit brand names. This segment also engages in the research and development, as well as contract manufacturing activities. Pfizer Inc. has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company for the development of Eliquis; Astellas Pharma US, Inc. for developing Xtandi; Merck KGaA for the development of Bavencio; and Neofluidics, LLC to develop a microfluidics-based platform. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Receive PFE News and Ratings via Email

Sign-up to receive the latest news and ratings for PFE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNYSE:PFE
CUSIP71708110
Phone212-733-2323

Debt

Debt-to-Equity Ratio0.47%
Current Ratio1.35%
Quick Ratio1.10%

Price-To-Earnings

Trailing P/E Ratio13.73
Forward P/E Ratio12.32
P/E Growth1.82

Sales & Book Value

Annual Sales$52.55 billion
Price / Sales4.12
Cash Flow$3.7503 per share
Price / Cash9.69
Book Value$12.02 per share
Price / Book3.02

Profitability

EPS (Most Recent Fiscal Year)$2.65
Net Income$21.31 billion
Net Margins40.55%
Return on Equity25.21%
Return on Assets9.42%

Miscellaneous

Employees90,200
Outstanding Shares5,952,870,000

How to Become a New Pot Stock Millionaire

Pfizer (NYSE:PFE) Frequently Asked Questions

What is Pfizer's stock symbol?

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

How often does Pfizer pay dividends? What is the dividend yield for Pfizer?

Pfizer declared a quarterly dividend on Monday, December 18th. Stockholders of record on Friday, February 2nd will be paid a dividend of $0.34 per share on Thursday, March 1st. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.74%. The ex-dividend date of this dividend is Thursday, February 1st. This is a positive change from Pfizer's previous quarterly dividend of $0.32. View Pfizer's Dividend History.

How will Pfizer's stock buyback program work?

Pfizer declared that its board has initiated a share buyback plan on Tuesday, December 19th 2017, which authorizes the company to buyback $10,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to reacquire shares of its stock through open market purchases. Shares buyback plans are usually a sign that the company's management believes its shares are undervalued.

How were Pfizer's earnings last quarter?

Pfizer (NYSE:PFE) released its quarterly earnings results on Tuesday, January, 30th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, topping the consensus estimate of $0.56 by $0.06. The biopharmaceutical company had revenue of $13.70 billion for the quarter, compared to analysts' expectations of $13.67 billion. Pfizer had a net margin of 40.55% and a return on equity of 25.21%. The company's revenue was up .6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.47 earnings per share. View Pfizer's Earnings History.

When is Pfizer's next earnings date?

Pfizer is scheduled to release their next quarterly earnings announcement on Tuesday, May, 1st 2018. View Earnings Estimates for Pfizer.

What guidance has Pfizer issued on next quarter's earnings?

Pfizer updated its FY18 earnings guidance on Tuesday, January, 30th. The company provided earnings per share (EPS) guidance of $2.90-3.00 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.78. The company issued revenue guidance of $53.5-55.5 billion, compared to the consensus revenue estimate of $53.82 billion.

What price target have analysts set for PFE?

19 equities research analysts have issued 12-month price objectives for Pfizer's shares. Their forecasts range from $31.00 to $43.00. On average, they expect Pfizer's stock price to reach $39.2222 in the next twelve months. View Analyst Ratings for Pfizer.

What are Wall Street analysts saying about Pfizer stock?

Here are some recent quotes from research analysts about Pfizer stock:
  • 1. According to Zacks Investment Research, "Pfizer faces headwinds in the form of genericization of key drugs, supply challenges in the legacy Hospira portfolio, pricing pressure and rising competition, which are hurting the top line. Nonetheless, we believe that new products like Ibrance, contribution from acquisitions, cost cuts and share buybacks should help the company achieve its guidance. Pfizer also boasts a strong pipeline and expects approximately 25 to 30 drug approvals over the next five years, including around 15 products that have blockbuster potential. Pfizer’s growing immuno-oncology portfolio offers a strong potential. Bavencio is being considered a key long-term growth driver for Pfizer. Additionally, Pfizer’s shares have outperformed the industry this year so far. Pfizer has a positive record of earnings surprises in recent quarters. Estimates have gone up slightly ahead of its Q1 earnings release." (4/12/2018)
  • 2. BMO Capital Markets analysts commented, "We are highly confident the deal will close as the purchase agreement removes IP risk and development risks, and creates significant shareholder value. We believe there is minimal risk for the deal being blocked due to anti-trust considerations CTP-543 Phase IIa initiated with top-line results expected 1Q18. The phase IIa trial will enroll approximately 100 patients spread across 4 active arms of differing doses (4, 8, 12 and 16 mg BID) and a placebo comparator. The primary endpoint for the trial will be measured using the severity of alopecia tool (SALT) after patients undergo 24 weeks of dosing. An additional 28 weeks of dosing of CTP-543 is planned for all patients enrolled in the study. If successfully developed, we anticipate a significant pricing discount for CTP-543 relative to Jakafi – owned by Incyte (INCY, Non-Rated). The earlier delay to initiate the trial due to clinical supply delays, which lasted around 2 months, has been resolved." (4/27/2017)

Are investors shorting Pfizer?

Pfizer saw a drop in short interest in March. As of March 29th, there was short interest totalling 98,318,686 shares, a drop of 31.2% from the March 15th total of 142,877,234 shares. Based on an average daily volume of 23,708,988 shares, the short-interest ratio is currently 4.1 days. Approximately 1.7% of the shares of the company are short sold.

Who are some of Pfizer's key competitors?

Who are Pfizer's key executives?

Pfizer's management team includes the folowing people:
  • Mr. Ian C. Read, Chairman & CEO (Age 64)
  • Mr. Frank A. D'Amelio, Exec. VP of Bus. Operations & CFO (Age 60)
  • Mr. Albert Bourla D.V.M., DVM, Ph.D., COO & Director (Age 56)
  • Dr. Mikael Dolsten, Pres of Worldwide R&D (Age 59)
  • Mr. John D. Young, Group Pres of Pfizer Innovative Health (Age 53)

Has Pfizer been receiving favorable news coverage?

Headlines about PFE stock have trended somewhat positive on Thursday, Accern reports. The research firm rates the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Pfizer earned a daily sentiment score of 0.14 on Accern's scale. They also assigned news headlines about the biopharmaceutical company an impact score of 44.39 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

How do I buy shares of Pfizer?

Shares of PFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pfizer's stock price today?

One share of PFE stock can currently be purchased for approximately $36.36.

How big of a company is Pfizer?

Pfizer has a market capitalization of $216.27 billion and generates $52.55 billion in revenue each year. The biopharmaceutical company earns $21.31 billion in net income (profit) each year or $2.65 on an earnings per share basis. Pfizer employs 90,200 workers across the globe.

How can I contact Pfizer?

Pfizer's mailing address is 235 EAST 42ND STREET, NEW YORK NY, 10017. The biopharmaceutical company can be reached via phone at 212-733-2323.


MarketBeat Community Rating for Pfizer (PFE)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  960 (Vote Outperform)
Underperform Votes:  511 (Vote Underperform)
Total Votes:  1,471
MarketBeat's community ratings are surveys of what our community members think about Pfizer and other stocks. Vote "Outperform" if you believe PFE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PFE will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Pfizer (NYSE:PFE) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
19 Wall Street analysts have issued ratings and price targets for Pfizer in the last 12 months. Their average twelve-month price target is $39.2222, suggesting that the stock has a possible upside of 7.93%. The high price target for PFE is $43.00 and the low price target for PFE is $31.00. There are currently 1 sell rating, 10 hold ratings and 8 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldBuyBuy
Consensus Rating Score: 2.372.422.562.53
Ratings Breakdown: 1 Sell Rating(s)
10 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
9 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
6 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
7 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $39.2222$39.3889$38.8750$38.3125
Price Target Upside: 7.93% upside9.75% upside6.39% upside6.93% upside

Pfizer (NYSE:PFE) Consensus Price Target History

Price Target History for Pfizer (NYSE:PFE)

Pfizer (NYSE:PFE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/13/2018Jefferies GroupSet Price TargetHold$38.00LowView Rating Details
4/12/2018CitigroupReiterated RatingSellMediumView Rating Details
4/11/2018Berenberg BankReiterated RatingNeutral$37.00LowView Rating Details
4/5/2018BarclaysDowngradeOverweight -> Equal Weight$41.00 -> $38.00MediumView Rating Details
4/2/2018BMO Capital MarketsSet Price TargetBuy$43.00MediumView Rating Details
1/31/2018Credit Suisse GroupBoost Price TargetNeutral -> Neutral$37.00 -> $39.00MediumView Rating Details
1/31/2018Leerink SwannBoost Price TargetMarket Perform -> Market Perform$35.00 -> $38.00MediumView Rating Details
1/31/2018UBSSet Price TargetBuy$42.00MediumView Rating Details
1/31/2018Morgan StanleyBoost Price TargetOverweight -> Buy$41.00 -> $43.00MediumView Rating Details
1/31/2018Societe GeneraleSet Price TargetNeutral$40.00MediumView Rating Details
1/30/2018Goldman SachsSet Price TargetNeutral$36.00HighView Rating Details
1/30/2018MorningstarSet Price TargetNeutral$38.00HighView Rating Details
1/30/2018Bank of AmericaSet Price TargetBuy$40.00MediumView Rating Details
1/30/2018JPMorgan ChaseReiterated RatingBuyLowView Rating Details
1/30/2018Sanford C. BernsteinSet Price TargetBuy$43.00LowView Rating Details
1/29/2018SunTrust BanksReiterated RatingHold -> Hold$33.00 -> $40.00LowView Rating Details
1/2/2018Nord/LBReiterated RatingNeutralLowView Rating Details
12/6/2017Deutsche BankSet Price TargetBuy$38.00LowView Rating Details
8/14/2017CowenSet Price TargetBuy$43.00LowView Rating Details
2/1/2017Atlantic SecuritiesSet Price TargetBuy$37.00N/AView Rating Details
1/21/2017Piper JaffraySet Price TargetBuy$53.00N/AView Rating Details
12/2/2016GuggenheimInitiated CoverageNeutralN/AView Rating Details
11/2/2016ArgusDowngradeBuy -> HoldN/AView Rating Details
5/4/2016Independent ResearchSet Price TargetNeutral$37.00N/AView Rating Details
(Data available from 4/19/2016 forward)

Earnings

Pfizer (NYSE:PFE) Earnings History and Estimates Chart

Earnings by Quarter for Pfizer (NYSE:PFE)

Pfizer (NYSE:PFE) Earnings Estimates

2018 EPS Consensus Estimate: $2.96
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183$0.67$0.75$0.72
Q2 20182$0.70$0.75$0.73
Q3 20182$0.75$0.78$0.77
Q4 20182$0.69$0.82$0.76

Pfizer (NYSE PFE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/1/2018$0.70N/AView Earnings Details
1/30/2018Q4 2017$0.5620$0.62$13.6746 billion$13.7030 billionViewListenView Earnings Details
10/31/2017Q3 2017$0.65$0.67$13.1749 billion$13.1680 billionViewN/AView Earnings Details
8/1/2017Q2 2017$0.65$0.67$13.0774 billion$12.8960 billionViewListenView Earnings Details
5/2/2017Q1 2017$0.67$0.69$13.0890 billion$12.7790 billionViewListenView Earnings Details
1/31/2017Q416$0.50$0.47$13.64 billion$13.60 billionViewN/AView Earnings Details
11/1/2016Q3$0.62$0.61$13.05 billion$13.05 billionViewN/AView Earnings Details
8/2/2016Q216$0.62$0.64$13.01 billion$13.10 billionViewN/AView Earnings Details
5/3/2016Q116$0.55$0.67$12.00 billion$13.00 billionViewN/AView Earnings Details
2/2/2016Q415$0.52$0.53$13.57 billion$14.05 billionViewN/AView Earnings Details
10/27/2015Q315$0.51$0.60$11.56 billion$12.10 billionViewListenView Earnings Details
7/28/2015Q215$0.52$0.56$11.39 billion$11.00 billionViewListenView Earnings Details
4/28/2015Q115$0.49$0.51$10.79 billion$10.86 billionViewN/AView Earnings Details
1/27/2015Q414$0.53$0.54$12.94 billion$13.10 billionViewN/AView Earnings Details
10/28/2014Q314$0.55$0.57$12.24 billion$12.40 billionViewN/AView Earnings Details
7/29/2014Q214$0.57$0.58$12.49 billion$12.80 billionViewN/AView Earnings Details
5/5/2014Q114$0.56$0.57$12.07 billion$11.35 millionViewN/AView Earnings Details
1/27/2014Q413$0.52$0.56$13.35 billion$13.56 billionViewN/AView Earnings Details
10/29/2013Q313$0.56$0.58$12.69 billion$12.64 billionViewN/AView Earnings Details
7/30/2013Q2 2013$0.55$0.56$13.02 billion$12.97 billionViewListenView Earnings Details
4/30/2013Q1 2013$0.55$0.54$14.10 billion$13.50 billionViewListenView Earnings Details
1/29/2013Q4 2012$0.44$0.47$14.40 billion$15.10 billionViewListenView Earnings Details
11/1/2012Q312$0.53$0.53$14.64 billion$14.00 billionViewN/AView Earnings Details
7/31/2012$0.54$0.62ViewN/AView Earnings Details
5/1/2012$0.57$0.58ViewN/AView Earnings Details
1/31/2012$0.47$0.50ViewN/AView Earnings Details
11/1/2011$0.55$0.62ViewN/AView Earnings Details
8/2/2011$0.59$0.60ViewN/AView Earnings Details
5/3/2011$0.59$0.60ViewN/AView Earnings Details
2/1/2011$0.46$0.47ViewN/AView Earnings Details
11/2/2010Q3 2010$0.51$0.54ViewN/AView Earnings Details
8/3/2010Q2 2010$0.52$0.62ViewN/AView Earnings Details
5/4/2010Q1 2010$0.53$0.60ViewN/AView Earnings Details
2/3/2010Q4 2009$0.49$0.49ViewN/AView Earnings Details
10/20/2009Q3 2009$0.48$0.51ViewN/AView Earnings Details
7/22/2009Q2 2009$0.46$0.48ViewN/AView Earnings Details
4/28/2009Q1 2009$0.48$0.54ViewN/AView Earnings Details
1/26/2009Q4 2008$0.60$0.65ViewN/AView Earnings Details
10/21/2008Q3 2008$0.60$0.62ViewN/AView Earnings Details
7/23/2008Q2 2008$0.54$0.55ViewN/AView Earnings Details
4/17/2008Q1 2008$0.65$0.61ViewN/AView Earnings Details
1/23/2008Q4 2007$0.47$0.52ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Pfizer (NYSE:PFE) Dividend Information

Pfizer pays an annual dividend of $1.36 per share, with a dividend yield of 3.74%. PFE's most recent quarterly dividend payment was Thursday, March 1. The company has grown its dividend for the last 8 consecutive years and is increasing its dividend by an average of 7.20% each year. Pfizer pays out 51.32% of its earnings out as a dividend.
Most Recent Dividend:3/1/2018
Annual Dividend:$1.36
Dividend Yield:3.74%
Dividend Growth:7.20% (3 Year Average)
Payout Ratio:51.32% (Trailing 12 Months of Earnings)
46.10% (Based on This Year's Estimates)
44.74% (Based on Next Year's Estimates)
Track Record:8 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Pfizer (NYSE:PFE)

Pfizer (NYSE:PFE) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
12/18/2017quarterly$0.343.68%2/1/20182/2/20183/1/2018
9/27/2017quarterly$0.323.6%11/9/201711/10/201712/1/2017
6/22/2017quarterly$0.323.75%8/2/20178/4/20179/1/2017
4/28/2017quarterly$0.323.77%5/10/20175/12/20176/1/2017
12/12/2016quarterly$0.323.9%2/1/20172/3/20173/1/2017
9/23/2016quarterly$0.303.5%11/8/201611/11/201612/1/2016
6/23/2016quarterly$0.303.53%8/3/20168/5/20169/1/2016
4/28/2016quarterly$0.303.67%5/11/20165/13/20166/1/2016
12/14/2015quarterly$0.303.72%2/3/20162/5/20163/2/2016
9/25/2015quarterly$0.283.63%11/4/201511/6/201512/1/2015
6/25/2015quarterly$0.283.3%8/5/20158/7/20159/2/2015
4/23/2015quarterly$0.283.18%5/6/20155/8/20156/2/2015
12/15/2014quarterly$0.283.65%2/4/20152/6/20153/3/2015
10/23/2014quarterly$0.263.57%11/5/201411/7/201412/2/2014
6/26/2014quarterly$0.263.51%7/30/20148/1/20149/3/2014
4/25/2014quarterly$0.263.38%5/7/20145/9/20146/3/2014
12/16/2013quarterly$0.263.45%2/5/20142/7/20143/4/2014
10/24/2013quarterly$0.243.14%11/6/201311/8/201312/3/2013
6/27/2013quarterly$0.243.43%7/31/20138/2/20139/4/2013
4/25/2013quarterly$0.243.19%5/8/20135/10/20136/4/2013
12/17/2012quarterly$0.243.74%1/30/20132/1/20133/5/2013
(Data available from 1/1/2013 forward)

Insider Trades

Pfizer (NYSE PFE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.06%
Institutional Ownership Percentage: 71.19%
Insider Trading History for Pfizer (NYSE:PFE)
Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Pfizer (NYSE PFE) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/13/2018Douglas M LanklerInsiderSell50,000$36.89$1,844,500.00133,057View SEC Filing  
3/13/2018Rady A JohnsonEVPSell27,323$36.55$998,655.6570,332View SEC Filing  
3/9/2018Mikael DolstenInsiderSell69,699$36.59$2,550,286.41120,784View SEC Filing  
3/6/2018Charles H HillInsiderSell42,393$35.76$1,515,973.68View SEC Filing  
3/2/2018Mikael DolstenInsiderSell13,986$35.85$501,398.10120,884View SEC Filing  
2/27/2018Sally SusmanEVPSell33,368$37.03$1,235,617.04191,505View SEC Filing  
2/27/2018W Don CornwellDirectorSell1,758$36.79$64,676.821,000View SEC Filing  
2/26/2018Kirsten Lund-JurgensenInsiderSell9,510$37.19$353,676.9036,959View SEC Filing  
12/15/2017Alexander R MackenzieInsiderSell6,750$37.00$249,750.00103,458View SEC Filing  
12/15/2017Rady A JohnsonEVPSell8,000$37.07$296,560.0046,963View SEC Filing  
11/1/2017Alexander R MackenzieInsiderSell14,700$35.30$518,910.00117,432View SEC Filing  
10/2/2017Alexander R MackenzieEVPSell7,350$35.65$262,027.50117,432View SEC Filing  
9/12/2017Sally SusmanInsiderSell38,230$35.00$1,338,050.00145,649View SEC Filing  
9/1/2017Alexander R MackenzieInsiderSell7,350$34.00$249,900.00124,774View SEC Filing  
8/31/2017Alexander R MackenzieInsiderSell7,350$34.00$249,900.00132,124View SEC Filing  
8/31/2017Frank A DamelioEVPSell94,409$34.00$3,209,906.00337,389View SEC Filing  
8/31/2017Ian C ReadCEOSell197,168$34.00$6,703,712.00580,318View SEC Filing  
8/21/2017Laurie J OlsonInsiderSell8,064$32.70$263,692.8074,506View SEC Filing  
8/7/2017Alexander R MackenzieInsiderSell15,000$33.50$502,500.00151,474View SEC Filing  
8/4/2017Ian C. ReadCEOSell96,950$34.00$3,296,300.00View SEC Filing  
3/10/2017Rady A JohnsonInsiderSell4,500$34.19$153,855.0054,963View SEC Filing  
3/9/2017Charles H HillInsiderSell36,000$34.07$1,226,520.0057,329View SEC Filing  
3/2/2017Mikael DolstenInsiderSell30,970$34.51$1,068,774.7064,719View SEC Filing  
11/9/2016Anthony J MaddalunaInsiderSell10,000$33.00$330,000.00112,087View SEC Filing  
11/4/2016Albert BourlaInsiderSell18,390$30.05$552,619.50149,199View SEC Filing  
5/26/2016Frank A DamelioEVPSell100,000$34.49$3,449,000.00472,994View SEC Filing  
5/24/2016Loretta V CangialosiVPSell86,000$33.97$2,921,420.00271,663View SEC Filing  
5/11/2016Laurie J OlsonEVPSell4,700$33.50$157,450.0071,659View SEC Filing  
5/10/2016Frank A DamelioEVPSell192,000$33.66$6,462,720.00564,994View SEC Filing  
5/10/2016John D YoungInsiderSell41,700$33.53$1,398,201.00200,399View SEC Filing  
5/9/2016Anthony J MaddalunaEVPSell8,950$33.75$302,062.5088,922View SEC Filing  
5/9/2016Ian C ReadCEOSell275,000$33.80$9,295,000.001,446,738View SEC Filing  
5/5/2016Sally SusmanEVPSell76,116$33.75$2,568,915.00195,951View SEC Filing  
5/4/2016Douglas M LanklerEVPSell29,700$33.69$1,000,593.00124,920View SEC Filing  
5/4/2016Mikael DolstenInsiderSell67,588$33.46$2,261,494.48438,107View SEC Filing  
5/3/2016Frank A DamelioEVPSell87,079$33.65$2,930,208.35372,994View SEC Filing  
10/6/2015Pfizer Incmajor shareholderBuy714,285$7.00$4,999,995.002,489,364View SEC Filing  
6/11/2015Laurie J OlsonEVPSell26,000$34.39$894,140.00View SEC Filing  
3/12/2015Sally SusmanEVPSell46,179$34.00$1,570,086.00View SEC Filing  
2/13/2015Loretta V CangialosiVPSell104,000$34.73$3,611,920.00View SEC Filing  
2/12/2015Anthony J MaddalunaEVPSell9,000$34.85$313,650.00View SEC Filing  
2/11/2015Frank A DamelioEVPSell14,800$34.30$507,640.00View SEC Filing  
2/10/2015Anthony J MaddalunaEVPSell9,000$33.78$304,020.00View SEC Filing  
12/8/2014Anthony J MaddalunaEVPSell6,500$32.00$208,000.00View SEC Filing  
11/10/2014Charles H HillEVPSell8,285$30.18$250,041.30View SEC Filing  
11/7/2014John D YoungInsiderSell21,600$29.89$645,624.00View SEC Filing  
10/29/2014Anthony J MaddalunaEVPSell2,425$29.56$71,683.00View SEC Filing  
6/12/2014Laurie J OlsonEVPSell36,275$29.53$1,071,200.75View SEC Filing  
6/2/2014Geno J GermanoInsiderSell30,000$29.68$890,400.00View SEC Filing  
3/17/2014John YoungInsiderSell9,000$31.38$282,420.0099,647View SEC Filing  
3/4/2014Loretta CangialosiVPSell102,943$32.05$3,299,323.15171,756View SEC Filing  
3/4/2014Mikael DolstenInsiderSell35,789$32.58$1,166,005.62344,571View SEC Filing  
3/4/2014Sally SusmanEVPSell67,585$32.59$2,202,595.15173,637View SEC Filing  
1/13/2014Frank DamelioEVPSell131,810$30.82$4,062,384.20356,451View SEC Filing  
11/1/2013Anthony J MaddalunaEVPSell43,500$31.02$1,349,370.00View SEC Filing  
11/1/2013Loretta V CangialosiVPSell10,000$31.20$312,000.00View SEC Filing  
10/28/2013Ian C ReadCEOSell338,000$30.57$10,332,660.00View SEC Filing  
9/16/2013Freda Lewis-HallEVPSell38,461$28.70$1,103,830.70118,383View SEC Filing  
7/31/2013Charles H HillEVPSell96,500$29.64$2,860,260.00View SEC Filing  
7/31/2013Loretta V CangialosiVPSell14,688$29.63$435,205.44View SEC Filing  
5/15/2013Amy W SchulmanEVPSell70,000$29.36$2,055,200.00View SEC Filing  
5/15/2013Ian C ReadCEOSell69,900$29.39$2,054,361.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Pfizer (NYSE PFE) News Headlines

Source:
DateHeadline
Pfizer (PFE) Given a $43.00 Price Target by Cowen AnalystsPfizer (PFE) Given a $43.00 Price Target by Cowen Analysts
www.americanbankingnews.com - April 19 at 12:16 PM
Pfizer (PFE) to Post FY2020 Earnings of $3.18 Per Share, SunTrust Banks ForecastsPfizer (PFE) to Post FY2020 Earnings of $3.18 Per Share, SunTrust Banks Forecasts
www.americanbankingnews.com - April 19 at 7:38 AM
How Analysts View Tetraphase Pharmaceuticals in April 2018How Analysts View Tetraphase Pharmaceuticals in April 2018
finance.yahoo.com - April 18 at 3:37 PM
BRIEF-IBT Urges Pfizer Shareholders To Vote For Proposal 7 For Corporate Political Spending DisclosureBRIEF-IBT Urges Pfizer Shareholders To Vote For Proposal 7 For Corporate Political Spending Disclosure
www.reuters.com - April 18 at 10:38 AM
SunTrust Banks Weighs in on Pfizers Q1 2018 Earnings (PFE)SunTrust Banks Weighs in on Pfizer's Q1 2018 Earnings (PFE)
www.americanbankingnews.com - April 18 at 7:52 AM
Coke Versus Pepsi of Drugmakers? Wall Street Doesnt Buy ItCoke Versus Pepsi of Drugmakers? Wall Street Doesn't Buy It
finance.yahoo.com - April 17 at 3:43 PM
Pfizer Inc. Stock Has a Great Storyline Thats Not Panning OutPfizer Inc. Stock Has a Great Storyline That's Not Panning Out
finance.yahoo.com - April 17 at 10:44 AM
J&J (JNJ) Tops Q1 Earnings Estimates, Raises Sales GuidanceJ&J (JNJ) Tops Q1 Earnings Estimates, Raises Sales Guidance
finance.yahoo.com - April 17 at 10:44 AM
Biovica International - Positive Results With DiviTum® From New Pfizer Study Presented at the AACR CongressBiovica International - Positive Results With DiviTum® From New Pfizer Study Presented at the AACR Congress
www.prnewswire.com - April 17 at 3:42 AM
Pfizer Inc. Stock Has a Great Storyline That’s Not Panning OutPfizer Inc. Stock Has a Great Storyline That’s Not Panning Out
investorplace.com - April 17 at 12:03 AM
Merck to move scientists and money toward promising cancer drugMerck to move scientists and money toward promising cancer drug
finance.yahoo.com - April 16 at 3:44 PM
Pfizer Doesnt Succeed In One Late-Stage Kidney Cancer Study, What Else Is Left On The Table?Pfizer Doesn't Succeed In One Late-Stage Kidney Cancer Study, What Else Is Left On The Table?
seekingalpha.com - April 16 at 10:27 AM
Pfizer (PFE) Short Interest Down 31.2% in MarchPfizer (PFE) Short Interest Down 31.2% in March
www.americanbankingnews.com - April 16 at 3:03 AM
Q1 2018 Earnings Forecast for Pfizer (PFE) Issued By Jefferies GroupQ1 2018 Earnings Forecast for Pfizer (PFE) Issued By Jefferies Group
www.americanbankingnews.com - April 16 at 1:17 AM
Brainstorm Health: Gene Editing Arms Race, Pfizer Duchenne Drug, Concentrated CaffeineBrainstorm Health: Gene Editing Arms Race, Pfizer Duchenne Drug, Concentrated Caffeine
fortune.com - April 14 at 3:20 PM
Berenberg Bank Analysts Give Pfizer (PFE) a $39.00 Price TargetBerenberg Bank Analysts Give Pfizer (PFE) a $39.00 Price Target
www.americanbankingnews.com - April 14 at 3:07 PM
Pfizer (PFE) Rating Increased to Outperform at BMO Capital MarketsPfizer (PFE) Rating Increased to Outperform at BMO Capital Markets
www.americanbankingnews.com - April 14 at 10:35 AM
Pfizer (PFE) Given a $35.00 Price Target at Jefferies GroupPfizer (PFE) Given a $35.00 Price Target at Jefferies Group
www.americanbankingnews.com - April 14 at 10:05 AM
Pfizer takes big gene therapy step after acquisition in Chapel HillPfizer takes big gene therapy step after acquisition in Chapel Hill
finance.yahoo.com - April 13 at 3:39 PM
Pfizer Starts Phase Ib for Duchenne Muscular Dystrophy DrugPfizer Starts Phase Ib for Duchenne Muscular Dystrophy Drug
finance.yahoo.com - April 13 at 3:39 PM
Mylan Denies Report It's Interested In Buying Merck KGaA's Consumer BizMylan Denies Report It's Interested In Buying Merck KGaA's Consumer Biz
finance.yahoo.com - April 13 at 3:39 PM
Tishman Speyer Inks Deal With Pfizer and Wins $1.8 Billion Construction LoanTishman Speyer Inks Deal With Pfizer and Wins $1.8 Billion Construction Loan
www.wsj.com - April 13 at 10:59 AM
Mylan Reportedly Interested Merck KGaA's Consumer Health UnitMylan Reportedly Interested Merck KGaA's Consumer Health Unit
finance.yahoo.com - April 13 at 10:59 AM
Pfizer (PFE) Given a $38.00 Price Target by Jefferies Group AnalystsPfizer (PFE) Given a $38.00 Price Target by Jefferies Group Analysts
www.americanbankingnews.com - April 13 at 9:39 AM
Dow Jones Component Pfizer Isn't Interested In Bristol — YetDow Jones Component Pfizer Isn't Interested In Bristol — Yet
finance.yahoo.com - April 12 at 3:40 PM
Pfizer (PFE) Rating Lowered to Hold at Zacks Investment ResearchPfizer (PFE) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - April 12 at 12:33 PM
Pfizer Doses First Patient Using Investigational Mini-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular ...Pfizer Doses First Patient Using Investigational Mini-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular ...
www.businesswire.com - April 12 at 11:33 AM
Pfizer Doses First Patient Using Investigational Mini-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular DystrophyPfizer Doses First Patient Using Investigational Mini-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
finance.yahoo.com - April 12 at 11:33 AM
Pfizer’s Inlyta Expansion Thwarted by Failed Phase III StudyPfizer’s Inlyta Expansion Thwarted by Failed Phase III Study
finance.yahoo.com - April 12 at 11:33 AM
Olumiant Could Boost Incyte’s RevenuesOlumiant Could Boost Incyte’s Revenues
finance.yahoo.com - April 12 at 11:33 AM
Pfizer Advances in Cancer Cell Therapy with Allogene AgreementPfizer Advances in Cancer Cell Therapy with Allogene Agreement
finance.yahoo.com - April 12 at 11:33 AM
Pfizers (PFE) "Sell" Rating Reiterated at CitigroupPfizer's (PFE) "Sell" Rating Reiterated at Citigroup
www.americanbankingnews.com - April 12 at 11:07 AM
UAB to receive funding from Pfizer for rheumatoid arthritis studyUAB to receive funding from Pfizer for rheumatoid arthritis study
finance.yahoo.com - April 11 at 3:38 PM
Pfizer (PFE) Rating Increased to Buy at Zacks Investment ResearchPfizer (PFE) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - April 11 at 1:48 PM
Pfizer Provides Update on Phase 3 Trial of Axitinib as Adjuvant Treatment for Patients at High Risk of Renal Cell ...Pfizer Provides Update on Phase 3 Trial of Axitinib as Adjuvant Treatment for Patients at High Risk of Renal Cell ...
www.businesswire.com - April 11 at 11:16 AM
Pfizer to Move Its Global Headquarters to Hudson Yards TowerPfizer to Move Its Global Headquarters to Hudson Yards Tower
www.bloomberg.com - April 11 at 11:16 AM
Pfizer's Kidney Cancer Drug Misses Endpoint in Phase IIIPfizer's Kidney Cancer Drug Misses Endpoint in Phase III
finance.yahoo.com - April 11 at 11:16 AM
Pfizer (PFE) Given a $37.00 Price Target by Berenberg Bank AnalystsPfizer (PFE) Given a $37.00 Price Target by Berenberg Bank Analysts
www.americanbankingnews.com - April 11 at 8:58 AM
Pfizer Joins the TriNetX Global Health Research Network Formed to Improve Clinical Trial Design and Accelerate the ...Pfizer Joins the TriNetX Global Health Research Network Formed to Improve Clinical Trial Design and Accelerate the ...
www.prnewswire.com - April 10 at 3:34 PM
[$$] Tishman Speyer Inks Deal With Pfizer and Wins $1.8 Billion Construction Loan[$$] Tishman Speyer Inks Deal With Pfizer and Wins $1.8 Billion Construction Loan
finance.yahoo.com - April 10 at 3:34 PM
Pfizer Provides Update on Phase 3 Trial of Axitinib as Adjuvant Treatment for Patients at High Risk of Renal Cell Carcinoma Recurrence After SurgeryPfizer Provides Update on Phase 3 Trial of Axitinib as Adjuvant Treatment for Patients at High Risk of Renal Cell Carcinoma Recurrence After Surgery
finance.yahoo.com - April 10 at 3:34 PM
Pfizer (PFE) Receives "Hold" Rating from Berenberg BankPfizer (PFE) Receives "Hold" Rating from Berenberg Bank
www.americanbankingnews.com - April 10 at 1:11 PM
Developer Tishman Speyer secures funds for $3.7 bln New York office towerDeveloper Tishman Speyer secures funds for $3.7 bln New York office tower
finance.yahoo.com - April 10 at 10:56 AM
Allogene Therapeutics Completes Agreement for Pfizers Allogeneic CAR T Immuno-oncology PortfolioAllogene Therapeutics Completes Agreement for Pfizer's Allogeneic CAR T Immuno-oncology Portfolio
www.businesswire.com - April 9 at 3:37 PM
Pharma’s Latest: Mergers and Acquisitions in 1Q18Pharma’s Latest: Mergers and Acquisitions in 1Q18
finance.yahoo.com - April 9 at 3:37 PM
Pfizer and Basilea Pharmaceutica: Cresemba Licensing AgreementPfizer and Basilea Pharmaceutica: Cresemba Licensing Agreement
finance.yahoo.com - April 9 at 3:37 PM
Exploring Collaboration between Pfizer and Sangamo TherapeuticsExploring Collaboration between Pfizer and Sangamo Therapeutics
finance.yahoo.com - April 9 at 3:37 PM
Pfizer and Sangamo Therapeutics: Hemophilia A Gene TherapyPfizer and Sangamo Therapeutics: Hemophilia A Gene Therapy
finance.yahoo.com - April 9 at 3:37 PM
Pfizer: Avoid Pfizer, Buy Johnson & JohnsonPfizer: Avoid Pfizer, Buy Johnson & Johnson
seekingalpha.com - April 9 at 10:53 AM
Pfizer Canada and MaRS Innovation Partner to Convert Great Science into Solutions to Benefit Canadians HealthPfizer Canada and MaRS Innovation Partner to Convert Great Science into Solutions to Benefit Canadians' Health
globenewswire.com - April 9 at 10:53 AM

SEC Filings

Pfizer (NYSE:PFE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Pfizer (NYSE:PFE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Pfizer (NYSE PFE) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.